Creatine May Supercharge Immune Cells That Fight Cancer, UCLA Study Finds
Key Takeaways
- A 2026 UCLA study published in iScience found that creatine powers dendritic cells — the immune cells that activate killer T cells against tumors.
- The creatine transporter gene was markedly elevated in dendritic cells inside tumors, suggesting they upregulate creatine uptake in the tumor environment.
- Dendritic cells without creatine showed impaired survival, reduced activation, and a weakened ability to prime T cells.
- Supplementing creatine in mouse models improved dendritic cell function and enhanced anti-tumor immune responses.
- This is preclinical research — it does not mean creatine is a cancer treatment, but it opens a new frontier in immune-metabolism science.
The Study: UCLA iScience, March 2026
A research team led by Prof. Lili Yang at UCLA's Department of Microbiology, Immunology and Molecular Genetics — in partnership with the Parker Institute for Cancer Immunotherapy — published a study in iScience on March 21, 2026 with a headline finding that caught the attention of immunologists and sports nutrition researchers alike: creatine powers dendritic cells, and dendritic cells are central to the body's ability to fight cancer.
The paper, titled Creatine Uptake Promotes Dendritic Cell Activation and Enhances Antitumor Immunity, was conducted in mouse models and human cell cultures. It builds directly on earlier work from the same lab showing that creatine fuels killer T cells in their battle against tumors. This study extends that finding one level deeper — to the cells that train the T cells in the first place.
The study was funded by the UCLA Broad Stem Cell Research Center (Rose Hills Foundation), the Jonsson Comprehensive Cancer Center, and the Tower Cancer Research Foundation.
What Are Dendritic Cells and Why Do They Matter?
Dendritic cells are specialized immune cells that act as the immune system's scouts and commanders. They patrol tissues, capture fragments of abnormal or foreign material — including pieces of cancer cells — and carry that information to the lymph nodes where they activate killer T cells (cytotoxic CD8+ T cells) to hunt and destroy the source.
Think of dendritic cells as the generals who identify the enemy and brief the soldiers. Without effective dendritic cell activation, the killer T cells do not know what to attack — or do not activate at full strength.
Most approved cancer immunotherapies — checkpoint inhibitors like pembrolizumab and nivolumab — work by targeting killer T cells directly, unleashing them from the molecular brakes that tumors use to suppress immune responses. These therapies have been transformative for some cancers. But only about 20–40% of patients respond to them. The researchers propose that part of the reason is that the dendritic cells feeding information to those T cells are themselves impaired — and that creatine is one reason why.
The Key Finding: Creatine Transporter Upregulation in Tumors
The study's core discovery came from examining the creatine transporter gene — the protein that pulls creatine from the bloodstream into cells — in dendritic cells from different environments.
The researchers found that the creatine transporter was markedly elevated in dendritic cells inside tumors compared to dendritic cells in healthy tissue. The cells were essentially signalling that they needed more creatine in the metabolically hostile tumor microenvironment. This upregulation suggested that creatine availability directly limits how well these cells can function when they are most needed.
To test the causal relationship, the team engineered dendritic cells that completely lacked the creatine transporter. Without the ability to import creatine, these cells showed:
- Impaired survival in the tumor microenvironment
- Reduced activation markers
- A weakened ability to stimulate T cell division
- Fewer signalling molecules (cytokines) needed to direct T cells to attack
When these creatine-deficient dendritic cells were grown alongside T cells in a lab dish, those T cells divided less frequently and produced fewer of the immune molecules used to kill cancer cells.
What Happened When Creatine Was Supplemented
The flip side of the knockout experiments was equally compelling. When dendritic cells were given additional creatine, they showed enhanced activation, improved survival in the tumor microenvironment, and a stronger ability to prime T cells for anti-tumor activity.
In mouse tumor models, supplementing creatine improved the dendritic cell response inside tumors and enhanced the overall anti-tumor immune response. The researchers observed more effective killer T cell recruitment and activation in tumors from creatine-treated mice compared to controls.
The study also explored the metabolic mechanism: creatine supports the phosphocreatine energy system inside dendritic cells, helping them maintain the high ATP levels needed to survive the metabolically hostile tumor microenvironment (tumors are notoriously glucose-depleted and oxygen-poor, which stresses immune cells trying to function within them).
What This Means — and What It Does Not
It is important to read this research carefully before drawing practical conclusions.
What it is: This is preclinical research — mouse models and human cell cultures. It demonstrates a compelling mechanistic link between creatine, dendritic cell function, and anti-tumor immunity, and it opens a new direction for investigating creatine's role in cancer immunotherapy. The authors explicitly propose that creatine supplementation or creatine-transporter-targeted strategies could be tested as adjuncts to existing immunotherapies to improve response rates.
What it is not: This is not evidence that taking creatine prevents or treats cancer. Mouse tumor models and cell cultures behave very differently from cancer in human patients. There are no clinical trials showing that creatine supplementation improves outcomes in cancer patients receiving immunotherapy — those trials would need to be designed, conducted, and published before any clinical recommendation could follow.
Why it matters for the science: The finding adds a third major cellular mechanism to creatine's immune portfolio — joining the already-documented role of creatine in powering killer T cells. If the dendritic cell finding translates to humans in clinical trials, it could provide a rationale for combining low-cost creatine supplementation with existing immunotherapy protocols to improve the 60–80% of patients who currently do not respond.
For now, creatine remains one of the safest, most studied, and most affordable supplements available — and the science around what it does in the body continues to expand well beyond athletic performance.
Creatine & Immunity: The UCLA 2026 Findings
- iScience Journal (Cell Press) — March 2026
- UCLA Parker Institute for Cancer Immunotherapy
- Dendritic cells The immune cell type creatine powers — trains killer T cells
- 20–40% Current immunotherapy response rate — why new approaches are needed
- Preclinical Current evidence stage — mouse models and cell cultures
Frequently Asked Questions
What did the UCLA creatine immune study find?
A March 2026 UCLA study published in iScience found that creatine powers dendritic cells — the immune cells that activate killer T cells against tumors. The creatine transporter gene was markedly elevated in dendritic cells inside tumors. Dendritic cells without creatine showed impaired survival and a weakened ability to train T cells. Supplementing creatine enhanced dendritic cell function and anti-tumor immune responses in mouse models.
Does creatine boost the immune system?
Emerging preclinical research suggests creatine supports immune cell function, particularly killer T cells and dendritic cells involved in anti-tumor immunity. However, this research is in mouse models and cell cultures — not human clinical trials. There is not yet enough evidence to recommend creatine as an immune booster in the way it is recommended for muscle and performance.
Can creatine help fight cancer?
Not based on current evidence. The UCLA study is preclinical (mouse models and cell cultures) and demonstrates a mechanistic link between creatine and immune cell function — not a clinical finding in cancer patients. The researchers propose creatine as a potential adjunct to immunotherapy, but this requires clinical trials before any recommendation can be made. Do not use creatine as a cancer treatment.
What are dendritic cells and why do they matter for immunity?
Dendritic cells are immune cells that capture fragments of abnormal material (including cancer cells), travel to lymph nodes, and activate killer T cells to attack the source. They are essentially the generals that brief the immune system's soldiers. If dendritic cells are impaired — as the UCLA study suggests happens in the energy-depleted tumor environment — killer T cells do not activate at full strength.
Who conducted the creatine immune system study?
The study was led by Prof. Lili Yang at UCLA's Department of Microbiology, Immunology and Molecular Genetics, in partnership with the Parker Institute for Cancer Immunotherapy. The paper was published in iScience (Cell Press) on March 21, 2026, with DOI 10.1016/j.isci.2026.115436.